Multimodality imaging has emerged as a key tool in improving our knowledge of cardiac amyloidosis. Due to the unreliability of animal models, imaging biomarkers are crucial in understanding the disease’s pathophysiology. Cardiac magnetic resonance (CMR) imaging has been particularly instrumental in this field. Moving forward, the focus is on comprehending the heart’s response to therapy, which is not only vital for prognosis but also for making personalized management decisions as treatment options continue to grow.

To know more: About the original article click here.